Adicet Bioincis A Clinical Stage Biotechnology Company Based In Redwood Citycaliforniaand Bostonmassachusettsthe Company Specializes In Developing Innovative Allogeneic Gamma Delta T Cell Therapies Aimed At Treating Autoimmune Diseases And Canceradicet Bio S Mission Is To Provide Best In Class Therapies That Leverage The Unique Capabilities Of Gamma Delta T Cellswhich Offer Novel Targeting And Tissue Homing Properties The Company S Pipeline Includes Several Promising Candidatessuch As Adi 001Which Is Currently In Clinical Trials For Lymphomaand Adi 270The First Gamma Delta Car T Cell Therapy In Clinical Development For Solid Tumors Like Clear Cell Renal Cell Carcinomaadicet Bio Is Committed To Advancing These Therapies Through Rigorous Research And Clinical Trialswith Preliminary Data Expected In 2025The Company Is Listed On The Nasdaq Under The Ticker Symbol Acet
